tradingkey.logo

tradingkey.logo
怜玢


LeonaBio Ord Shs

LONA
りォッチリストに远加
3.470USD
-0.260-6.97%
終倀 11-13 16:00ET
32.69M時䟡総額
損倱額盎近12ヶ月PER

LeonaBio Ord Shsに぀いお 䌁業名

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

LeonaBio Ord Shs プロフィヌル


䌁業コヌド- -
䌚瀟名- -
䞊堎日- -
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類- -
決算期末- -
本瀟所圚地- -
郜垂- -
蚌刞取匕所- -
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌド- -
䞊堎日- -
最高経営責任者「CEO」- -

LeonaBio Ord Shsの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
15.89K
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%

よくある質問

LeonaBio Ord Shsの䞊䜍5名の株䞻は誰ですか


LeonaBio Ord Shsの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Mark James Litton, Ph.D.

LeonaBio Ord ShsLONAの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、LeonaBio Ord Shsの株匏を保有しおいる機関は120瀟あり、保有株匏の総垂堎䟡倀は玄6.66Mで、党䜓の70.97%を占めおいたす。2025Q4ず比范しお、機関の持ち株は2319889.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。